Imuldosa

Ustekinumab, the active ingredient in Imuldosa, is a Interleukin-12/23 inhibitor presented as an intravenous formulation for use in adults with moderate to severe plaque psoriasis, psoriatic arthritis, or Crohn's disease. It targets key inflammatory pathways to reduce disease activity.

GNH USA supplies Imuldosa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Imuldosa is an interleukin‑12/23 inhibitor indicated for several chronic inflammatory conditions.

Plaque psoriasis: reduces skin lesions and inflammation. Psoriatic arthritis: improves joint symptoms and helps prevent structural damage. Moderate to severe Crohn's disease: induces and maintains remission of intestinal inflammation.

Common Side Effects: - Injection site reactions: redness, swelling, or pain at the infusion site. - Nasopharyngitis: mild upper‑respiratory tract infection symptoms. - Headache: transient mild to moderate headache. - Fatigue: feeling unusually tired. - Diarrhea: loose stools without severe dehydration. - Upper respiratory infection: cough, sore throat, or congestion.

Serious or Rare Side Effects: - Serious infections: tuberculosis, fungal, or opportunistic infections. - Malignancies: potential increased risk of certain cancers. - Hypersensitivity reactions: anaphylaxis, urticaria, or angioedema. - Exacerbation of inflammatory bowel disease: worsening of Crohn's symptoms. - Demyelinating disease: new or worsening neurologic disorders. - Cardiac events: rare cases of myocardial infarction or heart failure.

Before initiating therapy, clinicians should evaluate patient history and monitor for specific risks.

Screen for active infections: assess and treat any current infection prior to the first dose. Monitor for signs of infection: advise patients to report fever, cough, or unexplained illness. Assess tuberculosis risk: perform TB screening and treat latent infection when indicated. Consider vaccination status: administer required vaccines before starting therapy. Pregnancy and lactation: discuss potential risks with the healthcare provider. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ustekinumab may interact with other agents that affect immune function or vaccine efficacy.

Major Interactions (Avoid): - Live vaccines: contraindicated during treatment. - Concurrent immunosuppressants (e.g., azathioprine, methotrexate): may increase infection risk. - Cytokine modulators (e.g., interferon): potential additive immunosuppression.

Moderate Interactions (Monitor Closely): - Non‑live vaccines: may have reduced efficacy, monitor immune response. - Antibiotics for active infection: consider temporary discontinuation of ustekinumab. - Cytochrome P450 substrates: generally minimal effect, but monitor levels if clinically relevant.